Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Arvinas Holding Company ( (ARVN) ) has issued an update.
On October 5, 2025, Arvinas, Inc. announced positive Phase 1 clinical trial results for ARV-102, a PROTAC LRRK2 degrader, presented at the 2025 International Congress of Parkinson’s Disease and Movement Disorders. The trials, conducted on healthy volunteers and Parkinson’s disease patients, demonstrated that ARV-102 was well tolerated and showed dose-dependent increases in cerebrospinal fluid exposure, indicating brain penetration. Significant reductions in LRRK2 protein and pathway biomarkers were observed, supporting further development of ARV-102 for Parkinson’s disease and progressive supranuclear palsy. The company plans to present additional data in 2026 and initiate a Phase 1b trial for progressive supranuclear palsy.
The most recent analyst rating on (ARVN) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Arvinas Holding Company stock, see the ARVN Stock Forecast page.
Spark’s Take on ARVN Stock
According to Spark, TipRanks’ AI Analyst, ARVN is a Neutral.
Arvinas Holding Company’s overall stock score reflects significant financial challenges, including persistent losses and declining revenue, which weigh heavily on its valuation. While there is some technical strength and positive developments in clinical trials and partnerships, these are offset by financial restructuring and collaboration issues. Investors should be cautious, focusing on the company’s ability to improve its financial health and capitalize on its strategic initiatives.
To see Spark’s full report on ARVN stock, click here.
More about Arvinas Holding Company
Arvinas, Inc. is a clinical-stage biotechnology company focused on developing protein degradation therapies through its PROTAC platform. The company is dedicated to improving the lives of patients with debilitating and life-threatening diseases, targeting proteins involved in various conditions, including neurodegenerative disorders and cancers.
Average Trading Volume: 1,974,711
Technical Sentiment Signal: Hold
Current Market Cap: $705.5M
For an in-depth examination of ARVN stock, go to TipRanks’ Overview page.